Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung spot watch: new study tracks hazy lesions to predict cancer risk

NCT ID NCT03802981

Knowledge-focused Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 338 people who have two or more ground glass opacities (GGOs) in their lungs—small, hazy spots seen on CT scans. Instead of treating them right away, doctors will monitor them over time to learn more about how these spots behave and whether they lead to lung cancer. The goal is to gather information that could help guide future care for people with similar findings.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better understand which GGOs are dangerous and which are safe to watch, potentially reducing unnecessary treatments.
What could go wrong
This is an observational registry, not a treatment trial. It may not provide clear answers about how to manage GGOs, and results may take years to emerge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

338 people

The number who actually took part.

Started

Jan 2019

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with GGOs or mixed subsolid pulmonary nodules may be recruited from participating Thoracic Oncology Surgical Group (TSOG) sites, in accordance with local institutional practice and referral patterns, and assessed for eligibility based on the criteria listed below.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age greater than 18 years * Have two or more GGOs on initial CT imaging * GGOs must be measure ≤3.0 cm and ≥0.6 cm in the greatest dimension * GGOs must be greater than half ground glass A biopsy is not necessary for inclusion in the trial. Biopsy of a GGO, even with a diagnosis of adenocarcinoma, does not necessarily preclude enrollment in this surveillance protocol. In other words, patients with a diagnosis of adenocarcinoma are still eligible, at the discretion of the clinician and/or investigator, if they meet the above criteria. Exclusion Criteria: * Patients who are actively undergoing lung cancer treatment or have a history of lung cancer, except for cases of completely resected pathologic stage IA nonsmall cell lung cancer (NSCLC). Patients with stage IA NSCLC and multiple GGOs can enroll in this active surveillance protocol after complete resection of the NSCLC and confirmation of stage on final pathologic assessment. * The presence of any solid lesion ≥0.6 cm suspicious for malignancy. * Patients who are actively undergoing treatment for other malignancies

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple ground glass opacities (GGOS)

Contacts and locations

Locations

  • Allegheny Health Network

    Pittsburgh, Pennsylvania, 15212, United States

  • Baylor University Medical Center

    Houston, Texas, 77030, United States

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

  • Centre Hospitalier de l'Université de Montreal

    Montreal, Quebec, H2L 4M1, Canada

  • Duke University Medical Center

    Durham, North Carolina, 27701, United States

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

  • George Washington University School of Medicine

    St Louis, Missouri, 63110, United States

  • Hartford Healthcare

    Hartford, Connecticut, 06102, United States

  • Lehigh Valley Health Network

    Allentown, Pennsylvania, 18103, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030-4009, United States

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts, 02114, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • McMaster University (Data Collection Only)

    Hamilton, Ontario, L8N 3Z5, Canada

  • Memorial Sloan Kettering Basking Ridge

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Bergen

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Commack

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Westchester

    Harrison, New York, 10604, United States

  • New York Presbyterian Hospital

    New York, New York, 10065, United States

  • Roswell Park Cancer Institute (Data Collection Only)

    Buffalo, New York, 14263-0001, United States

  • Rush University Medical Center (Data collection only)

    Chicago, Illinois, 606012, United States

  • Stanford University Medical Center (Data collection only)

    Stanford, California, 94305-5408, United States

  • Temple University

    Philadelphia, Pennsylvania, 19140, United States

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania, 19107, United States

  • University Health Network

    Toronto, Ontario, M5G 2C4, Canada

  • University of California San Diego

    San Diego, California, 92103, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • University of Pennsylvania (Data Collection Only)

    Philadelphia, Pennsylvania, 19104, United States

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15213, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.